U.S., China Cease-Fire on Tariffs Only Kicks the Can Down the Road
President Trump lauded his meeting with Chinese President Xi Jinping at the G20 summit in Buenos Aires as "extraordinary" after the two sides agreed to a pause in tariff increases for 90 days. But Hagar Chemali, CEO of Greenwich Media Strategies, said investors shouldn't start the ticker tape parade just yet.
Make no mistake, a temporary cease-fire in what was becoming a full-fledged trade war gives both sides time to cool off and re-assess, said Chemali. "At least both nations agree that they don't want to go down this path of economic cold war."
But the agreement was "not very substantive" and did not get to the root of the issues that led to tariffs, according to Chemali.
Trump holds most of the leverage going into the 90-day cool-off period, since the U.S. was prepared to increase tariffs on $200 billion worth of goods up to 25 percent after the first of the year. But Chemali said that without the united front of our allies' support, it may be harder for China to back down, especially on unresolved issues relating to the country's theft of American intellectual property.
In 90 days, don't be surprised to hear about another 90-day extension, she said.
For full interview [click here](https://cheddar.com/videos/trump-leaves-g20-with-trade-truce).
The health and wellness industry is booming, expected to hit $14 trillion by 2032. Equinox teamed up with Function Health to revolutionize health optimization.
Featherie, a line of sustainable and functional golf wear for girls, fills a void in the market, catering to the increasing number of female junior golfers.
The CEO of LiveOne, Rob Ellin, discusses the DOJ's lawsuit against Live Nation and Ticketmaster, how will if affect you and the future of live events. Watch!
Nvidia did a record $26 billion in sales in the latest quarter. And get ready for the stock to keep climbing, because the A.I. boom is just getting started.
In honor of National Cancer Research Month, Perspective Therapeutics discusses its latest treatment — currently in clinical trials — that targets cancer cells d